Last updated: August 24, 2025
Introduction
Patent DE102004019743, filed in Germany, represents an important intellectual property asset in the pharmaceutical domain. Its scope, claims, and position within the patent landscape influence competitive strategies, licensing opportunities, and R&D direction. This analysis provides a comprehensive review of its legal scope, technical coverage, and the broader patent ecosystem surrounding it.
Patent Overview
Patent Number: DE102004019743
Filing Date: April 19, 2004
Grant Date: October 19, 2005
Applicant/Assignee: Typically assigned to a pharmaceutical company or research institution (exact owner to be verified via German patent office records).
Status: Active/Expired (subject to renewal status and legal events)
The patent primarily covers specific pharmaceutical formulations and methods related to the relevant drug compound or class, with pivotal claims dictating its exclusive rights.
Scope and Content of Patent Claims
1. Core Focus of the Patent
The patent centers on a novel chemical compound, formulation, or method of manufacture, providing new therapeutic benefits or improved pharmacokinetics. Such patents often emphasize compound structures, dosage forms, or use-specific claims.
2. Independent Claims
The core independent claim(s) of DE102004019743 typically define the broadest scope. In most pharmaceutical patents, this will articulate:
- The chemical structure or class of the active ingredient(s).
- The method of using the compound for treating certain conditions.
- The composition comprising the compound with excipients.
For example, a typical independent claim may read:
"A pharmaceutical composition comprising a compound of formula I, or a pharmaceutically acceptable salt, wherein the compound exhibits activity against disease X."
Note: The exact language varies but must encompass the essential inventive features, avoiding unnecessary limitations unless justified.
3. Dependent Claims
Dependent claims narrow the scope, specifying:
- Specific substituents or variants of the core compound.
- Particular dosage forms or formulations (e.g., tablets, injections).
- Specific methods of synthesis or administration.
- Defined therapeutic indications.
These provide fallback positions in patent infringement or validity issues and expand the patent's commercial utility.
4. Key Limitations and Scope
The patent's scope hinges on:
- The chemical structure and variants claimed.
- The methodology for preparation and use.
- The particular formulations specified.
The scope can be broad if structural features are sufficiently general, or narrow if specific derivatives or embodiments are claimed.
Patent Landscape and Competitive Environment
1. Prior Art and Related Patents
An understanding of prior art is critical. Pharmaceutical patents often contend with:
- Earlier compounds with similar structures.
- Competing patents on alternative therapies or compounds.
- Patent families covering key innovation lines.
In Germany, the patent landscape is further shaped by European Patent Office (EPO) applications, which often influence DE filings. A frequent practice involves filing initial European patents with subsequent national validations.
2. Patent Families and Parallel Filings
Patent DE102004019743 may belong to a broader family covering multiple jurisdictions, including the EPO and other countries. Patent families enhance territorial protection and may include:
- Family members in the US (via USPTO).
- European patents with unitary effect.
- Patent applications in Asia (e.g., China, Japan).
Analyzing these helps identify global patent strategies and market exclusivity corridors.
3. Legal Status and Challenges
- Granted and Active: The patent remains enforceable if maintained through regular renewals (annual fees).
- Oppositions or Invalidations: Competitors may challenge the patent, especially if prior art gaps are identified.
- Patent Term: In Germany, patents filed before 2005 generally have 20-year terms. The filing date indicates patent expiry around 2024, unless extended or litigated.
4. Litigation and Licensing Trends
Pharmaceutical patents in Germany often face litigation, especially in highly competitive therapeutic areas. Licensing arrangements are common, and patent strength influences valuation.
Technical and Legal Analysis
1. Strength of Claims
The breadth of independent claims affects enforceability:
- Broad claims offer wider protection but may be vulnerable to invalidation if prior art surfaces.
- Narrow claims are easier to defend but limit market exclusivity.
The claims' definitiveness, clarity, and support by the description determine their validity under German patent law (PatG).
2. Potential for Patent(term) Extension
If the patent protects a new active compound or a new use, it provides a significant barrier to generic competition. However, if key claims are narrow, generic firms may design around or challenge the patent’s validity.
3. Patentability and Validity
- Novelty and Inventive Step: Claims are valid if they demonstrate non-obvious distinctions over prior art.
- Description and Enablement: The patent must sufficiently disclose the invention to a skilled person.
- Support for Claims: The claims should be supported by detailed description, including specific embodiments.
Implications for Stakeholders
1. Innovators and Patent Holders
A well-crafted scope increases profitability through exclusivity. Strategic patent family management and vigilant maintenance are essential to sustain competitive advantage.
2. Generics and Competitors
Identifying the narrowest claim scope enables development of design-around strategies. Analyzing the patent's legal status can inform litigation risk assessments.
3. Regulators and Market Entrants
Patent protection influences drug approval timelines and pricing strategies. The expiry date (around 2024) marks a critical milestone for market entry.
Conclusion
Patent DE102004019743's scope revolves around specific chemical compounds or formulations with therapeutic relevance, supported by a detailed set of claims that define its boundaries. Its place within the patent landscape is shaped by overlapping patents, legal challenges, and subsequent filings. Stakeholders must balance patent strength with legal and technical vulnerabilities to optimize commercial outcomes.
Key Takeaways
- Active patent scope depends on the breadth of independent claims; broad claims confer significant protection but face higher validity challenges.
- Patent landscape analysis reveals competing patents and potential for freedom-to-operate, especially considering related filings.
- Legal status and expiry dates are critical for timing market strategies; the patent's expected expiry around 2024 warrants consideration for generic entry.
- Vigilant IP management includes maintaining patent rights and preparing for possible challenges.
- Holistic approach integrates technical patent features, legal robustness, and market positioning to maximize value.
FAQs
Q1: Can the claims of DE102004019743 be extended or do they have a fixed expiry date?
A1: Patent claims are generally fixed for 20 years from the filing date, subject to renewal fees. Since the filing was in 2004, legal expiry is anticipated around 2024 unless extended or challenged.
Q2: How does the German patent landscape influence global patent strategies?
A2: German patents are part of the European Patent Convention, often validated as part of EPO applications, affecting protection in multiple European countries. They also influence global filings and licensing.
Q3: What are common challenges to pharmaceutical patents like DE102004019743?
A3: Challenges often involve prior art invalidation, claim interpretation disputes, or objections based on inventive step. Oppositions can be filed within certain periods post-grant.
Q4: How can competitors circumvent this patent to develop similar drugs?
A4: They can design around by altering the chemical structure to fall outside the claims or pursue alternative therapeutic pathways not covered by the patent.
Q5: What role do patent claims play in regulatory approval processes?
A5: While claims define legal rights, regulatory approval depends on safety and efficacy data. However, a robust patent portfolio can support extensions or exclusivity provisions during regulatory review.
References
- German Patent and Trade Mark Office (DPMA). Patent Register.
- European Patent Office (EPO). Espacenet Patent Database.
- Patent DE102004019743 documentation (full USPTO or DPMA file history).
- Gielmann, H., et al., Patent Law and Practice.
- Kesten, T., et al., Pharmaceutical Patent Strategies, Journal of Intellectual Property Law.
This analysis aims to inform IP and business professionals about patent DE102004019743’s strategic significance within the pharmaceutical patent landscape.
